Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial
|
|
- Roland Bryant
- 6 years ago
- Views:
Transcription
1 Endovascular Therapy vs. Open Femoral Endarterectomy Rationale and Design of the Randomized PESTO Trial Prof. Thomas Zeller, MD Department Angiology Clinic for Cardiology and Angiology II University Heart-Center Freiburg - Bad Krozingen Bad Krozingen, Germany
2 Faculty Disclosure Thomas Zeller, MD For the 12 months preceding this presentation, I disclose the following types of financial relationships: Honoraria received from: Abbott Vascular, Bard Peripheral Vascular, Veryan, Biotronik, Boston Scientific Corp., Cook Medical, Cordis Corp., Gore & Associates, Medtronic, Spectranetics, Straub Medical, TriReme, VIVA Physicians Consulted for: Boston Scientific Corp., Cook Medical, Gore & Associates, Medtronic, Spectranetics, Veryan Research, clinical trial, or drug study funds received from: 480 biomedical, Bard Peripheral Vascular, Veryan, Biotronik, Cook Medical, Cordis Corp., Gore & Associates, Medtronic, Spectranetics, Terumo, TriReme, Volcano
3 CFA Standard Treatment Open surgical revascularisation Thrombendartherectomy atheromateous lesions Embolectomy embolic lesions Limitations: Scarred tissue Obesity Morbidity up to 5%: Major hematoma Wound infection Surgical revision Cardon A et al. Endarteriectomy of the femoral tripod: long-term results and analysis of failure factors. Ann Chir 2001;126:
4 CFA Standard Treatment - Complications 1513 patients undergoing elective CFE in the 2007 to 2010 National Surgical Quality Improvement Project database were examined. 30-day mortality rate: 1.5% Postoperative morbidities: cardiac (1.0%) pulmonary (1.9%) renal (0.4%) urinary tract infection (1.7%) thromboembolic (0.5%) neurologic (0.4%) sepsis (2.7%) superficial (6.3%) and deep surgical site complications (2.0%) At least 1 complication: 7.9% Siracuse JJ 1, Gill HL, Schneider DB, Graham AR, Connolly PH, Jones DW, Meltzer AJ. Assessing the perioperative safety of common femoral endarterectomy in the endovascular era. Vasc Endovascular Surg Jan;48(1):27-33.
5 Subgroup Analysis Stented lesions vs. non-stented lesions Stented (n = 133) Nonstented (n = 227) OR 95% CI P Value Failure 2.2% 10.1% 0.20 ( ) Complications 7.5% 5.7% 1.34 ( ) Restenosis 20.0% 31.8% 0.53 ( ) Year TLR 13.1% 23.6% 0.49 ( ) Bonvini et al. JACC 2011
6 Femoro-popliteal Artery - Biomechanics CFA CFA CFA-bifurcation Zone A Zone B Zone C Zone D Bend / Kink Compress / Slight curve Fixed Bend / Kink Modified according to Lansky, A; Angiographic Analysis of Strut Fractures in the SIROCCO Trial. TCT 2004
7 Stent Fractures Distal EIA
8 The Potential New Solution: Drug Coated Balloon angioplasty with or w/o upfront atherectomy / mechanical thrombectomy
9 Subgroup Analysis Atherectomy vs. POBA +/- Stent Atherectomy (N=25) % PTA ±stent (N=335) % RR 95% CI P value Failures Complications Restenosis yr TLR Bonvini et al. JACC 2011
10
11 Atherectomy of the Common Femoral Artery The Bad Krozingen Experience
12 Baseline characteristics N= 286 Mean Age (years): 71 (range 44-93) men 200 (69.9%) CVR Diabetes 101 (35.3%) Hypertension 257 (89.9%) Hyperlipidemia 257 (89.9%) Smoking 194 (67.8%) Coronary heart disease 142 (49.7%) History of stroke 32 (11.2%) COPD 30 (10.5%) Renal failure 82 (28.7%)
13 Atherectomy- and Protection devices N % Silverhawk Turbohawk / Rockhawk / HawkOne Protection device (Spider) Adjunctive Therapy n % Stenting Plain old balloon angioplasty Drug-coated balloon
14 Acute Results Mean Target lesion (TL) stenosis pre intervention (visual) Mean TL stenosis post intervention (visual) Procedural success ( 30% residual TL stenosis) 82.1% 24.2% 255 (89.9%) ABI pre intervention 0.53 ABI post intervention 0.85 (P=0.001)
15 Results at 1 year/2 years N (%) Target lesion revascularization (TLR) at 1 year 13 (4.5) Endovascular 6 (2.1) Surgery 7 (2.3) Target lesion revascularization (TLR) at 2 years 28 (9.8) Endovascular 15 (5.3) Surgery 13 (4.5)
16 PESTO-CFA Study Percutaneous Intervention versus Surgery in the Treatment of Common Femoral Artery Lesions A prospective, multi-centre, randomised study Title: PESTO-CFA Aim: Study design: Patient recruitment: Non inferiority study comparing DCB based endovascular therapy and surgical therapy in the treatment of atherosclerotic CFA disease Prospective, multicenter, randomized, controlled study, 1:1 randomization Follow-up at 6 months, 1, 2 and 5 years 260 patients. Study duration 6.5 years (recruitment time 18 months, follow-up 5 years)
17 PESTO-AFC Study Design DESIGN: Prospective, randomized, multicentre study Aim: Evaluation of acute- and midterm results of atherectomy and DCB compared to TEA in the treatment of CFA disease. Hypothesis: non-inferiority 260 patients to be enrolled in 10 clinical sites in Germany Endovascular - Atherectomy/DCB - Stent (optional) Colloquium consensus Randomization 1:1 Surgery Endarterectomy 6-, 12-, and 24-months FU - ABI-measurement - Treadmill test (optional) - Duplex-ultrasound - Walking-impairment Questionaire
18 PESTO-AFC Main Inclusion Criteria General criteria: - Age 21 years - Written informed consent - Ability to undergo the procedures and follow-up visits - Symptomatic PAOD Fontaine IIa-IV / Rutherford 2-5 Duplex/Angiography/CTA/MRA criteria: - De-novo CFA occlusion or stenosis > 70% diameter reduction including the femoral bifurcation - At least one patent tibial artery - No untreated inflow stenosis > 50%, intervention in the same session possible (true for surgery and endovascular study arm) - Study lesion must be suitable for both treatment modalities (colloquium consensus)
19 PESTO-AFC Primary Endpoints Primary Endpoint (Efficacy) Primary patency rate of target lesion without TLR at 12 months (duplexsonographic patency defined as PSVR < 2.5). Primary Endpoint (Safety) Combined 30-day Endpoint: - Periinterventional/-operative complications including death, MI, major-/minor amputation of target limb. - Access site complications. - Thrombo-embolic events. - Index-procedure related infections.
20 Summary Endovascular Treatment of CFA Disease Surgery is still considered as the gold standard for CFA treatment Limited availability of controlled data Peripheral intervention techniques have reached comparable technical outcomes compared to surgery including Stenting Atherectomy w/o DCB RCT s comparing endovascular treatment with surgery are on the way
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD Faculty Disclosure Thomas Zeller, MD For the 12 months preceding this presentation, I disclose the following types of
More informationMichael K.W. Lichtenberg, MD
Ranger All-Comer Registry Treatment of femoropopliteal atherosclerotic lesions using the Drug eluting Balloon Ranger: An All Comers Registry Michael K.W. Lichtenberg, MD Klinikum Arnsberg Arnsberg, Germany
More informationPreliminary 6-month results of VMI-CFA trial
Preliminary 6-month results of VMI-CFA trial Koen Deloose, MD Head Vascular Surgery, AZ Sint Blasius, Dendermonde, Belgium Disclosure slide Speaker name: Koen Deloose, MD I have the following potential
More informationRANGER SFA REGISTRY Interim Analysis. Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators
RANGER SFA REGISTRY Interim Analysis Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a
More informationCOMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert
COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions Dierk Scheinert Department of Angiology University Hospital Leipzig, Germany Disclosure
More informationLong-term results with interwoven nitinol stents vs. BMS vs. DCB
Long-term results with interwoven nitinol stents vs. BMS vs. DCB Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany Disclosure Advisory Board /Consultant: Abbott,
More informationDo we really need a stent in long SFA lesions? No: DEB is the answer
Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany My Disclosures: Advisory Board: Medtronic-Invatec,
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationWhy and where do I use mechanical debulking for the treatment of arterial occlusions?
Why and where do I use mechanical debulking for the treatment of arterial occlusions? Prof. Thomas Zeller Department Angiology University Heart-Center Freiburg - Bad Krozingen Bad Krozingen, Germany Faculty
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationMichael K. W. Lichtenberg MD, FESC on behalf of KANSHAS 1 investigators; Tepe G, Müller-Hülsbeck S, Deloose K, Verbist J, Goverde P, Zeller T
Interim 30-day analysis from the KANSHAS 1 study of the novel KANSHAS drug coated balloon for treatment of femoropopliteal occlusive disease; a latest first-in-human study Michael K. W. Lichtenberg MD,
More informationTOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
More informationWilliam A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, PA USA
William A. Gray MD System Chief of Cardiovascular Services, President, Wynnewood, PA USA Why atherectomy? Calcification is the norm not the exception Most trials do not include heavy calcification There
More informationRotarex mechanical debulking: The Leipzig experience in patients
Rotarex mechanical debulking: The Leipzig experience in 1.200+ patients Dierk Scheinert, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Dierk Scheinert
More informationAtherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System
Atherectomy is Still Live and Effective John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System Why is Atherectomy Still Alive? Improved devices Better data
More informationISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany
ISR-treatment The Leipzig experience with purely mechanical debulking Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich I have the following
More information6-month 0utcomes of a Novel Sirolimus Coated DCB Technology Evaluated in SFA Thomas Zeller, MD University Heart Center Freiburg-Bad Krozingen
First Report of the SELUTION Trial: 6-month 0utcomes of a Novel Sirolimus Coated DCB Technology Evaluated in SFA Thomas Zeller, MD University Heart Center Freiburg-Bad Krozingen On behalf of the SELUTION
More informationEffPac - Trial: Assessment of the Effectiveness of DCB versus POBA in the SFA Ulf Teichgräber, MD, MBA
EffPac - Trial: Assessment of the Effectiveness of DCB versus POBA in the SFA Ulf Teichgräber, MD, MBA Leipzig, 24.01.2017 Prof. Dr. Ulf Teichgräber - LINC 2017 2 Disclosure of conflict of interest Speaker
More informationDierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany
The RANGER clinical trial programme: 12-month results from the RANGER RCT and first look at the COMARE I study of RANGER vs. IN.PACT for femoropopliteal lesions Dierk Scheinert, MD Department of Angiology
More informationReal PTX RCT: 3 year data from a randomized comparison of DCB vs. DES in femoropopliteal lesions
Real PTX RCT: 3 year data from a randomized comparison of DCB vs. DES in femoropopliteal lesions Dierk Scheinert, MD Department of Angiology University of Leipzig, Germany Disclosure Dierk Scheinert, MD
More informationDCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
More informationUpdate on the Ranger clinical trial programme
Update on the Ranger clinical trial programme Dierk Scheinert, MD Universitätsklinikum Leipzig, Leipzig, Germany on behalf of the RANGER SFA investigators Disclosure Speaker s name: Dierk Scheinert I have
More informationClinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
More informationLatest Insights from the LEVANT II study and sub-group analysis
Latest Insights from the LEVANT II study and sub-group analysis Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University-Hospital Leipzig, Germany Conflicts of Interest Advisory Board
More informationFabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
Don t Use Risky and Embolizing Drug Coated Balloons Below The Knee! Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationDevice Evolution. Atherectomy: Where Do We Stand After 12 Years Since FDA Clearance. Where Do We Stand? 4/18/2015
Disclosure Statement of Financial Interest Atherectomy: Where Do We Stand After 12 Years Since FDA Clearance Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationLutonix DCB in BTK Update on the BTK real world registry and RCT
Lutonix DCB in BTK Update on the BTK real world registry and RCT Prof. Dr. med. Dierk Scheinert Department of Interventional Angiology University Hospital Leipzig Disclosures Speaker: Prof. Dr. med. Dierk
More informationLong Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA
Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA Disclosures John R. Laird Within the past 12 months, I or my spouse/partner have had a
More informationAtherectomy: Jetstream and Directional. George S. Chrysant, M.D.
Atherectomy: Jetstream and Directional George S. Chrysant, M.D. Disclosures Abbott Vascular: MAB, consultant, proctor Abiomed: consultant Boston Scientific: MAB, consultant, proctor Medicines Company:
More informationCurrent Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis Osamu Iida, MD From the Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan. ABSTRACT: Approximately
More informationThe ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
More informationThe present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
More information12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany
12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany Disclosure Speaker name: Gunnar Tepe I have the following potential conflicts
More information2-YEAR DATA SUPERA POPLITEAL REAL WORLD
2-YEAR DATA SUPERA POPLITEAL REAL WORLD Enrique M. San Norberto. Angiology and Vascular Surgery. Valladolid University Hospital. Valladolid. Spain. Disclosure Speaker name: ENRIQUE M. SAN NORBERTO I have
More informationWhen and how to use distal protection devices for lower extremity revascularization. Peter A. Schneider, MD Kaiser Foundation Hospital, Honolulu
When and how to use distal protection devices for lower extremity revascularization Peter A. Schneider, MD Kaiser Foundation Hospital, Honolulu Disclosure Peter A. Schneider Potential conflicts of interest
More informationClinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry
Clinical use and safety of the Lutonix DCB for the treatment of BTK: interim data from a prospective registry Alexander Zimmermann Department of Vascular and Endovascular Surgery Klinikum rechts der Isar
More informationMaximizing Outcomes in a complex population with Drug-coated balloon
Maximizing Outcomes in a complex population with Drug-coated balloon March 13, 2018 Chumpol Wongwanit, MD Siriraj Hospital, Mahidol University, Bangkok, Thailand LINC Asia-Pacific 2018, Hong Kong Disclosure
More informationDisclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA
In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA Disclosures No financial disclosures. Cameron M. Akbari, MD, MBA, FACS Site Director, Vascular Surgery Medstar
More informationA randomized comparison of endovascular versus surgery treatment of common femoral artery disease: Results from the TECCO trial
A randomized comparison of endovascular versus surgery treatment of common femoral artery disease: Results from the TECCO trial (TECCO randomized clinical trial, NCT01353651) Y. Gouëffic, N. Della Schiava,
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationUpdate from Korea on the Lutonix SFA registry 12 month data
Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries
More informationPotential Conflicts of Interest
DES-BTK: A Prospective, Double-Blind Randomized Trial of Polymer-Free Sirolimus-Eluting Stents Compared to Bare Metal Stents in Patients with Infrapopliteal Disease Aljoscha Rastan, MD, Gunnar Tepe, MD,
More informationAre DES and DEB worth the cost in BTK interventions?
Are DES and DEB worth the cost in BTK interventions? Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen, Germany -1- My Disclosures: Advisory Board: Medtronic-Invatec, Gore,
More informationAlternative concepts for drug delivery in BTK arteries the LIMBO project
Alternative concepts for drug delivery in BTK arteries the LIMBO project Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Speaker s name: Dierk
More informationMEET M. Bosiers K. Deloose P. Peeters. SFA stenting in 2009 : The good and the ugly What factors influence patency?
MEET 2009 SFA stenting in 2009 : The good and the ugly What factors influence patency? M. Bosiers K. Deloose P. Peeters 1 TASC II 2007 vs TASC 2000 Type A Type B Type C Type D 2000 < 3 cm 3-5 cm < 3 cm
More informationThe latest generation DEB
The latest generation DEB V. Riambau, MD. PhD Prof. and Chief of Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona University of Barcelona Consultant: Bolton Medical/ Medtronic/
More informationCritical limb ischemia due to an occlusion of an aorto-biiliac prothesis step by step case presentation and decision making
Critical limb ischemia due to an occlusion of an aorto-biiliac prothesis step by step case presentation and decision making Dr. Özgün Sensebat Vascular and general surgeon Vascular Private Clinic Dorsten
More informationSpecificities for infrapopliteal stents
Specificities for infrapopliteal stents Nicolas Diehm, M.D. Swiss Cardiovascular Center Clinical and Interventional Angiology University Hospital Bern, Switzerland Disclosures Speaker`s Bureau: MEDRAD,
More informationCutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD
Current Treatment of Femoropopliteal Instent Restenosis Professor of Medicine Medical Director of the Vascular Center UC Davis Medical Center SFA In-stent Restenosis Common: 18%- 40% at 12 months in recent
More informationShockwave Medical Lithoplasty. Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany
Shockwave Medical Lithoplasty Thomas Zeller MD Universitäts-Herzzentrum Freiburg & Bad Krozingen, Germany Disclosure Speaker name: Thomas Zeller, MD I have the following potential conflicts of interest
More informationIs combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
More informationEfficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
More informationComparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationThe Illumina FIH study with a next generation DES 12-months results
The Illumina FIH study with a next generation DES 12-months results Dierk Scheinert, MD Head of Medical Department V - Angiology University of Leipzig Medical Center, Germany Disclosure Dierk Scheinert,
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationHow do I use mechanical debulking for the treatment of arterial occlusions
How do I use mechanical debulking for the treatment of arterial occlusions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich
More informationDisclosures. Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long?
Rational Selection of Endovascular Options for the SFA and Popliteal: What Works Where and for How Long? UCSF Vascular Symposium 2017 April 6-8, 2017 San Francisco, CA Disclosures Consulting, Speakers
More informationContemporary use of DCBs, Ranger clinical trial and investigator sponsored research
Contemporary use of DCBs, Ranger clinical trial and investigator sponsored research Dierk Scheinert, MD Division of Interventional Angiology University-Hospital, Leipzig, Germany IMPORTANT INFORMATION:
More informationExcimer Laser angioplasty for femoro-popliteal disease. Sendai Kousei Hospital, Tokyo Kamata Hospital Naoto Inoue MD, FSCAI, FJCC, FAHA
Excimer Laser angioplasty for femoro-popliteal disease Sendai Kousei Hospital, Tokyo Kamata Hospital Naoto Inoue MD, FSCAI, FJCC, FAHA Speaker s name: Naoto Inoue I have the following potential conflicts
More informationDEB in Periphery: What we Know Till Now
DEB in Periphery: What we Know Till Now Karl-Ludwig Schulte Vascular Center Berlin Ev. Hospital Königin Elisabeth St. Gertrauden Hospital Charité, CC13, Humboldt-University Berlin www.vascular-center-berlin.com
More informationUse of Laser In BTK Disease (CLI)
Use of Laser In BTK Disease (CLI) Click to edit academic affiliation, practice or hospital logo(s) of preference. Product and/or sponsor logos not permitted, per CME guidelines. Richard Kovach, MD, FACC,
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationThe Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology
The Crack and Pave technique for highly resistant calcified lesions Manuela Matschuck MD University Hospital Leipzig Department Angiology Disclosure Speaker name: Dr. med. Manuela Matschuck I have the
More informationLessons learnt from DES in the SFA is there any ideal concept so far?
Wednesday, January 25, 2017 - Time: 11:49-11:55 DEEP DIVE SESSION: Lower limb interventions (part II) Lessons learnt from DES in the SFA is there any ideal concept so far? S.Müller-Hülsbeck, MD, EBIR,
More informationRotarex mechanical thrombectomythe first line option for thrombotic occlusions?
Rotarex mechanical thrombectomythe first line option for thrombotic occlusions? Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany Disclosure Advisory Board /Consultant:
More informationBilateral use of the Gore IBE device for bilateral CIA aneurysms and a first interim analysis of the prospective Iceberg registry
Bilateral use of the Gore IBE device for bilateral CIA aneurysms and a first interim analysis of the prospective Iceberg registry Michel MPJ Reijnen, MD, PhD Department of Vascular Surgery, Rijnstate Hospital
More informationDrug-coated balloons in BTK:
Drug-coated balloons in BTK: Where do we stand and what are the open questions? Dr. Marc Bosiers LINC 2019 - Leipzig My disclosures x o I do not have any potential conflicts of interest to report o I have
More informationLUTONIX DCB in BTK Update on the BTK clinical program & single center experience
LUTONIX DCB in BTK Update on the BTK clinical program & single center experience Prof. Dr. med. Dierk Scheinert Department of Interventional Angiology University Hospital Leipzig Disclaimer 1. The information
More informationUpdate in femoral angioplasty & stenting PRO
MEET 2008 Update in femoral angioplasty & stenting Will extra-long stents be a solution for SFA disease? PRO Patrick Peeters, MD Chief department Cardiovascular & Thoracic Surgery, Imelda Hospital, Bonheiden,
More informationNovel concept for drug delivery in infrapopliteal arteries The LIMBO trial
Novel concept for drug delivery in infrapopliteal arteries The LIMBO trial Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Advisory
More informationBioMimics 3D in my Clinical Practice
BioMimics 3D in my Clinical Practice M Lichtenberg M.D. Vascular Centre Arnsberg / German Venous Centre Arnsberg CAUTION: Investigational Device. Limited by Federal (or United States) Law to Investigational
More informationUpdate on the Levant 2 Clinical Trial Programme. Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany
Update on the Levant 2 Clinical Trial Programme Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have the following potential conflicts of interest
More informationWhich Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA
Which Stent Is Best for Various Femoropopliteal Anatomy? 2018 Pacific Northwest Endovascular Conference June 15-26, 2018 Seattle, WA Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationAtherectomy with thrombectomy of. Rotarex S : The Leipzig experience
Atherectomy with thrombectomy of femoropopliteal occlusions with Rotarex S : The Leipzig experience Dr. Bruno Freitas, Prof., MD Department of Interventional Angiology, Universität Leipzig, Germany Santa
More informationThe Utility of Atherectomy and the Jetstream Atherectomy System
The Utility of Atherectomy and the Jetstream Atherectomy System William A. Gray, MD Columbia University Medical Center 2014 Boston Scientific Corporation or its affiliates. All rights reserved. IMPORTANT
More informationThe Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience
The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have
More informationGetting to answers with clinical trials: Being bold
Getting to answers with clinical trials: Being bold Prof. Thomas Zeller Department Angiology University Heart-Center Freiburg - Bad Krozingen Bad Krozingen, Germany Thomas Zeller, MD Faculty Disclosure
More informationCould a combination of DCB + stent be the answer in complex SFA lesions
Could a combination of DCB + stent be the answer in complex SFA lesions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationCalcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease
Calcium Removal and Plaque Modification in the Era of DEB and Contemporary Stenting for Femoro- Popliteal Disease Thomas M. Shimshak, MD Heart and Vascular Center Florida Hospital Heartland Medical Center
More informationOne Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller
One Year after In.Pact Deep: Lessons learned from a failed trial Prof. Dr. Thomas Zeller Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: x Consulting:
More informationHybrid Procedures for Peripheral Obstructive Disease - Step by Step -
Hybrid Procedures for Peripheral Obstructive Disease - Step by Step - Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery Disclosure Speaker name:..holger Staab... I have
More informationNicolas W Shammas, MD, MS
Rota%onal and Aspira%on Atherectomy in Trea%ng in- Stent Restenosis of Femoropopliteal Arteries: Final Results of the JETSTREAM- ISR Feasibility Study Nicolas W Shammas, MD, MS President and Research Director,
More informationNew Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008
New Trials in Progress: ACT 1 Jon Matsumura, MD Cannes, France June 28, 2008 Faculty Disclosure I disclose the following financial relationships: Consultant, CAS training director, and/or research grants
More informationPeripheral Vascular Disease
Peripheral artery disease (PAD) results from the buildup of plaque (atherosclerosis) in the arteries of the legs. For people with PAD, symptoms may be mild, requiring no treatment except modification of
More informationSafety and Feasibility of Intravascular Lithotripsy for Treatment of Common Femoral Artery Stenoses
Safety and Feasibility of Intravascular Lithotripsy for Treatment of Common Femoral Artery Stenoses Pr Marianne Brodmann, MD Univ. Klinik für Innere Medizin Medizinische Universtität Graz 1 Disclosure
More informationDCB + BMS is not a DES
DCB + BMS is not a DES Fabrizio Fanelli, MD, EBIR Professor of Radiology Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy Disclosures Consultant
More informationSFA CTO Lesion Management laser or directional atherectomy?
SFA CTO Lesion Management laser or directional atherectomy? Kevin, Chung-Ho Hsu, M.D. Setion of Peripheral Vascular Disease, Division of Cardiology, China Medical University Hospital, Taichung, Taiwan
More informationThe BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA
The BATTLE Trial Comparing Bare Metal to Drug Eluting Stents for Intermediate Length Lesions of the SFA BATTLE RCT investigators: Y. Gouëffic, A. Sauguet, P. Desgranges, P. Feugier, E. Rosset, E. Ducasse,
More informationDiagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC
Diagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC Interventional Cardiologist/Endovascular Specialist Bradenton Cardiology Center Bradenton,
More informationAre RCT always needed: Experience with objective performance criteria (OPC)
Are RCT always needed: Experience with objective performance criteria (OPC) Peter A. Schneider, MD Krishna Rocha-Singh, MD Kaiser Foundation Hospital Honolulu, Hawaii Prarie Heart Institute Springfield,
More informationLuminor DCB in femoropopliteal lesions
Luminor DCB in femoropopliteal lesions EffPac trial results and solo DCB study design Marcus Thieme, MD Department of Angiology/ Cardiology/ Diabetology Regiomed Vascular Center Sonneberg Clinic for Internal
More informationNew Data to Shape the Era of Drug Elution in Peripheral Interventions
New Data to Shape the Era of Drug Elution in Peripheral Interventions William A. Gray MD Director of Endovascular Services Columbia University Medical Center New York Lower Extremity Endovascular - Interventions
More informationSix Month Results of the Global BIOLUX P-III All-Comers Registry using Drug Coated Balloon in Infra-Inguinal Artery Disease
Six Month Results of the Global BIOLUX P-III All-Comers Registry using Drug Coated Balloon in Infra-Inguinal Artery Disease Prof. Dr. Gunnar Tepe, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX
More informationIs a Stent or Scaffold Necessary in The SFA?
1 2 3 Is a Stent or Scaffold Necessary in The SFA? Stents were developed to optimize acute results after angioplasty Specifically, stents are universally accepted to manage flow limiting dissections and
More informationSAFETY AND EFFECTIVENESS OF ENDOVASCULAR REVASCULARIZATION FOR PERIPHERAL ARTERIAL OCCLUSIONS
SAFETY AND EFFECTIVENESS OF ENDOVASCULAR REVASCULARIZATION FOR PERIPHERAL ARTERIAL OCCLUSIONS LIBBY WATCH, MD MIAMI VASCULAR SPECIALISTS MIAMI CARDIAC & VASCULAR INSTITUTE FINANCIAL DISCLOSURES None 2
More information